---
title: "Opdivo (nivolumab), all indications: Specific populations questions"
description: "Specific populations questions on Opdivo (nivolumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Does kidney or liver impairment affect Opdivo clearance? Is Opdivo safe during pregnancy? Can patients breastfeed while receiving Opdivo? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/opdivo/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab), all indications: Specific populations questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)  
Indication pages: [Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)

## Specific populations

<a id="opdivo-organ-impairment"></a>

### Does kidney or liver impairment affect Opdivo clearance?

> “The following factors had no clinically important effect on the clearance of nivolumab: 
> age (29 to 87 years), weight (35 to 160 kg), sex, race, baseline LDH, PD-L1 expression, solid tumor 
> type, tumor size, renal impairment (eGFR ≥ 15 mL/min/1.73 m<sup>2</sup>), and mild (total bilirubin [TB] 
> less than or equal to the ULN and AST greater than ULN or TB greater than 1 to 1.5 times ULN 
> and any AST) or moderate hepatic impairment (TB greater than 1.5 to 3 times ULN and any AST). 
> Nivolumab has not been studied in patients with severe hepatic impairment (TB greater than 
> 3 times ULN and any AST).”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

## Pregnancy and breastfeeding

<a id="opdivo-pregnancy"></a>

### Is Opdivo safe during pregnancy?

> “Based on data from animal studies and its mechanism of action [see Clinical Pharmacology 
> (12.1)], OPDIVO can cause fetal harm when administered to a pregnant woman. In animal 
> reproduction studies, administration of nivolumab to cynomolgus monkeys from the 
> onset of organogenesis through delivery resulted in increased abortion and premature infant 
> death (see Data). Human IgG4 is known to cross the placental barrier and nivolumab is an 
> immunoglobulin G4 (IgG4); therefore, nivolumab has the potential to be transmitted from the 
> mother to the developing fetus. The effects of OPDIVO are likely to be greater during the second 
> and third trimesters of pregnancy. There are no available data on OPDIVO use in pregnant women 
> to evaluate a drug-associated risk. Advise pregnant women of the potential risk to a fetus.”

Source: [OPDIVO: OPDIVO, page 32, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=32)

> “Verify the pregnancy status of females of reproductive potential prior to initiating OPDIVO 
> [see Use in Specific Populations (8.1)].
> Contraception
> OPDIVO can cause fetal harm when administered to a pregnant woman [see Use in Specific 
> Populations (8.1)]. Advise females of reproductive potential to use effective contraception during 
> treatment with OPDIVO and for 5 months following the last dose.”

Source: [OPDIVO: OPDIVO, page 33, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=33)

<a id="opdivo-breastfeeding"></a>

### Can patients breastfeed while receiving Opdivo?

> “There are no data on the presence of nivolumab in human milk, the effects on the breastfed 
> child, or the effects on milk production. Because of the potential for serious adverse reactions 
> in the breastfed child, advise women not to breastfeed during treatment and for 5 months 
> after the last dose of OPDIVO.”

Source: [OPDIVO: OPDIVO, page 33, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=33)

## Related pages
- [Medical information: Opdivo (nivolumab): All indications](https://www.evicenter.com/medical-information/opdivo)
- [Indication](https://www.evicenter.com/medical-information/opdivo/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/opdivo/safety)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo/storage-and-supply)
